Drug Profile


Alternative Names: SARC 023; STA-9090

Latest Information Update: 24 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Synta Pharmaceuticals
  • Developer Cancer Research UK; Cardiff University; Emory University; Innsbruck Medical University; Madrigal Pharmaceuticals; Memorial Sloan-Kettering Cancer Center; Multiple Myeloma Research Consortium; Synta Pharmaceuticals
  • Class Antineoplastics; Indoles; Resorcinols; Small molecules; Triazoles
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Non-small cell lung cancer
  • Discontinued Acute lymphoblastic leukaemia; Acute myeloid leukaemia; Breast cancer; Chronic myeloid leukaemia; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Hepatocellular carcinoma; Liver cancer; Malignant melanoma; Mesothelioma; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Rectal cancer; Sarcoma; Small cell lung cancer

Most Recent Events

  • 01 Mar 2017 Synta Pharmaceuticals terminates a phase II trial due to weak accrual in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy, Unresectable/ Inoperable) in USA (IV) (NCT01551693)
  • 05 Dec 2016 Medical University Innsbruck suspends enrolment in a phase-I/II clinical trial in Ovarian cancer (Combination therapy, Second-line therapy or greater) in Austria, Belgium, France and Germany (IV) (NCT02012192)
  • 03 Dec 2016 Discontinued - Clinical-Phase-Unknown for Head and neck cancer (Neoadjuvant therapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top